The PRWIRE Press Releases https:// 2020-05-20T12:24:16Z Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus 2020-05-20T12:24:16Z strong-effectiveness-of-nanoviricides-drug-candidates-observed-in-an-animal-model-of-infection-by-an-ace2-using-human-coronavirus      May 20, 2020 - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases.NanoViricides is developing an animal model for coronavirus infection using hCoV-NL63 as a surrogate for SARS-CoV-2, the virus that causes COVID-19 disease. HCoV-NL63 is a circulating human coronavirus that causes a disease that is similar to SARS-CoV-2, but much milder. Both viruses utilize the same cell receptor, namely ACE2, to gain entry into the cell. Because it causes a mild disease, hCoV-NL63 can be used in BSL2 environments, and the Company believes it is a useful surrogate for development of therapeutics against SARS-CoV-2 infection.In this lethal direct-lung-infection model, animals in all groups developed lung disease which later led to multi-organ failures, a clinical pathology resembling that of the SARS-CoV-2. Reduction in loss of body weight at day 7 was used as the primary indicator of drug effectiveness. Rats were infected directly into lungs with lethal amounts of hCoV-NL63 virus particles and then different groups were treated separately with five different nanoviricides drug candidates, remdesivir as a positive control, and the vehicle as a negative control. The treatment was intravenous by tail-vein injection once daily for five days, except in the case of remdesivir wherein it was by tail-vein injection twice daily.Animals treated with the five different nanoviricides showed significantly reduced body weight loss. The body weight loss was only 3.9% for the best nanoviricide candidate, ranging to 11.2% for the potentially least effective one, as compared to 20% in the vehicle-treated control group, in female animals (n=5 in each group). Male animals treated with the same nanoviricides also showed significantly reduced body weight loss. The body weight loss in male animals was 8.0% for the best nanoviricide candidate and ranged up to 10.9% for the potentially least effective one, as compared to 25% in the vehicle-treated control group (n=5 in each group). In comparison, remdesivir treatment led to a body weight loss of 15.2% in females and 18.6% in males in this study (see below). Smaller numbers mean less loss in body weight compared to starting body weight in the group, and indicate greater drug effectiveness.The strong effectiveness of nanoviricide drug candidates in this model is consistent with the effectiveness observed in cell culture studies against infection of both hCoV-NL63, which was used in this study, and hCoV-229E, another circulating coronavirus that uses a distinctly different receptor, namely APN.Thus this study corroborates the previous cell-culture effectiveness reported by the Company and provides confidence to the Company that these nanoviricides drug candidates may be expected to result in a clinical candidate to be pursued in human clinical trials.The Company believes the fact that these nanoviricides anti-coronavirus drug candidates are highly effective against two distinctly different coronaviruses that use different cellular receptors is very significant. Specifically, it provides a rational basis to scientists indicating that even if the SARS-CoV-2 coronavirus mutates, the nanoviricides can be expected to continue to remain effective.Importantly, nanoviricides are designed to act by a novel mechanism of action, trapping the virus particle like the "Venus-fly-trap" flower does for insects. Antibodies, in contrast, only label the virus for other components of the immune system to take care of. It is well known that the immune system is not functioning properly at least in severe COVID-19 patients.The Company believes that these nanoviricides drug candidates are potentially superior to favipravir, based on cell culture studies and may be superior to remdesivir based on the results of this study, however, a definite conclusion to that effect cannot be drawn. Oral favipravir and infusion of remdesivir are two anti-viral drugs in clinical trials for the treatment of COVID-19.Prior to filing for human clinical trials, NanoViricides plans on conducting studies to further determine the effectiveness against SARS-CoV-2, perform drug development studies for safety/toxicology, and request a pre-IND Meeting with the US FDA for regulatory guidance.Human coronavirus NL63 (hCoV-NL63) uses the same ACE2 receptor as the SARS-CoV-2 that causes CoVID-19. Both in terms of its clinical pathology, and its receptor usage, it is known to be very similar to SARS-CoV-2, except much milder. Therefore the Company believes hCoV-NL63 is a good surrogate model for therapeutics development against SARS-CoV-2. HCoV-NL63 can be studied in a BSL2 lab whereas SARS-CoV-2 currently requires a BSL3 or BSL4 facility.The striking difference in weight loss between the two sexes in this animal model was remarkable. It has been widely reported that men are more likely to suffer severe infection and fatalities from SARS-CoV-2 than women in the current pandemic. This feature was replicated in our animal model study indicating that biological sex differences are the driver of the differences in the severity of infection by the coronaviruses that utilize the ACE2 receptor.The various receptors used by different coronaviruses appear to fall in the broad family of membrane-associated serine proteases. As a family, they share several structural features. Their substrate specificities are dictated by specific amino acid residues and their positions. However, the coronaviruses do not appear to insert into the specific substrate sites on their receptors as can be broadly deduced from limited, available knowledge of these interactions. NanoViricides believes that this has made it possible for the Company to develop receptor-mimetic virus-binding ligands that have broad-spectrum effectiveness against multiple coronaviruses that use different receptors.HCoV-NL63 is known to cause severe lower respiratory tract infections in young children leading to hospitalization. The symptoms are generally less severe than SARS-CoV-2 but are similar. In most cases, hCoV-NL63 causes relatively mild disease, often associated with croup, bronchiolitis, and lower respiratory tract disease in children, and is considered to cause some of the common colds in adults. Thus, the clinical manifestation of hCoV-NL63 infection in pediatric patients is similar to that of SARS-CoV-2, although much less severe. SARS-CoV-2 causes clinically similar milder forms of disease in most patients, but moderate to severe disease requiring hospitalizations in about 15-20% of infected persons. These similarities imply that hCoV-NL63 should be a reasonable model virus for antiviral cell culture and animal studies in BSL2 environment in the course of antiviral drug development for SARS-CoV-2.About NanoViricidesNanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company does not currently have a license to the coronavirus field, however, TheraCour has not denied any licenses to the Company. The Company typically begins the licensing process only after demonstrating effectiveness of some candidates in optimization stage.This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.As with any drug development efforts, there can be no assurance that any of these candidates would show sufficient effectiveness and safety for human clinical development at this time.There can be no assurance that the Company will be successful in establishing the necessary collaborations, although the Company has been successful at establishing necessary collaborations for its drug programs in the past.FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls". Trintech Releases 2020 Global Record to Report Benchmark Report 2020-05-12T16:09:38Z trintech-releases-2020-global-record-to-report-benchmark-report      May 13, 2020 - Trintech, a leading provider of financial software solutions, today announced the release of its 2020 Global Record to Report Benchmark Report. Trintech surveyed almost 200 enterprise companies across 31 countries through January 2020 to evaluate which parts of the Record to Report (R2R) process have been automated, which are in the process of being automated and where finance and accounting (F&A) organizations are looking to adopt automation in the future.Key findings from the survey on the trends in R2R automation include:- Reconciliations are currently the single biggest challenge for F&A organizations- A growing number of organizations identify a lack of standardization across all processes as their main roadblock to efficiency- Looking ahead to 2025, respondents expect their biggest challenges will be personnel related, as attracting and retaining talent becomes more critical"Automating low-value, repetitive tasks completed by the office of finance is finally starting to gain traction - we see the interest in the benefits of financial automation growing each year," said David King, Chief Marketing Officer at Trintech. "These insights show that there is a huge potential for organizations to achieve significant ROI through the implementation of automation technology. Now, more than ever, organizations are looking for ways to be more efficient, while increasing transparency and ensuring data integrity as part of their month end or quarter end close. The office of finance is providing insights almost daily now that are crucial for business decisions across every industry."In terms of organizations' current automation practices, only 20% of respondents have "Established" or "Advanced" automation in place. The report's findings also show that most organizations are at least starting the move towards automating some parts of their office of finance, and there are few laggards that have not started implementing automation at all."Organizations need to spend more time understanding risk and less time managing data - approaches that deliver that efficiently and effectively, and drive quality into the process, have immense value," said Jim O'Connor, Managing Principal Advisory Practice at The Hackett Group.To dive into the results of this benchmark report further, Trintech and The Hackett Group will be hosting a joint webinar, How to Prepare Your Organization for the Future of Financial Automation, on Thursday, May 14th, to give companies insight into topics such as:- The biggest challenges for the month end process- Roadblocks to having the most efficient process- The maturity of financial close automation- Key areas to focus on improving by 2025Read the full Record to Report (R2R) Benchmark Report here. https://pr.report/H8G3eY14About TrintechTrintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting and bank fee analysis, to governance, risk and compliance - Trintech's portfolio of financial solutions, including Cadency(R) Platform, Adra(R) Suite, and targeted tools, ReconNET(TM), T-Recs(R), and UPCS(R), help manage all aspects of the financial close process. Over 3,500 clients worldwide - including the majority of the Fortune 100 - rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands and the Nordics, as well as strategic partners in South Africa, Latin America and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook and Twitter.About The Hackett GroupThe Hackett Group (NASDAQ: HCKT) is an intellectual property-based strategic consultancy and leading benchmarking and best practices firm to global companies, with offerings that include smart automation and enterprise cloud application implementation. Services include business transformation, enterprise analytics, global business services, and working capital management. The Hackett Group also provides dedicated expertise in business strategy, operations, finance, human capital management, strategic sourcing, procurement and information technology, including its award-winning Oracle and SAP practices.The Hackett Group has completed nearly 18,000 benchmarking studies with major corporations and government agencies, including 93% of the Dow Jones Industrials, 90% of the Fortune 100, 80% of the DAX 30 and 57% of the FTSE 100. These studies drive its Best Practice Intelligence Center(TM) which includes the firm's benchmarking metrics, best practices repository and best practice configuration guides and process flows, which enable The Hackett Group's clients and partners to achieve world-class performance.More information on The Hackett Group is available at: www.thehackettgroup.com, info@thehackettgroup.com, or by calling (770) 225-3600. Cyber Company to Supply 50M Health "COVI-PASS(TM)" 2020-05-08T06:56:17Z cyber-company-to-supply-50m-health-covi-pass-tm      - Cyber tech company signs technology deal to supply 50M "COVI-PASS(TM)" Digital Health Passports to 15 countries- VST Enterprises signs deal with digital health technology company - Circle Pass Enterprises - to supply its patented VCode(R) technologies to create the world's most secure digital health passport - COVI-PASS(TM)- Cyber Company is committed to working closely with governments & major stakeholders to deploy safe & trusted technology solution for COVID-19 pandemic May 8, 2020 - International Digital Health Technology firm Circle Pass Enterprises (CPE) has signed a deal with VST Enterprises Ltd (VSTE) the British cyber security company founded by tech entrepreneur Louis-James Davis (31) to integrate its state-of-the-art VCode(R) & VPlatform(R) technologies into the COVI-PASS(TM) Digital Health Passport. Louis-James Davis CEO VST Enterprises Powered by VST Enterprises groundbreaking cyber security technology VCode(R) & VPlatform(R), Circle Pass Enterprises has contracted with VST Enterprises for a fully secure Digital Health Passport - COVI-PASS(TM), to be paired with approved testing kits. CPE is to start shipping orders from next week for the first phased release of 50M COVI-PASS(TM) Digital Health Passports to both the private sector and Governments in over 15 countries, including Italy, Portugal, France, Panama, India, the US, Canada, Sweden, Spain, South Africa, Mexico, United Arab Emirates and The Netherlands.The COVI-PASS(TM) Digital Health Passport works on an intelligent colour mapping system (green, amber, red) to authenticate and validate a COVID-19 test providing test history and relevant health information. This allows for accurate data metrics to assess those who have tested positive and negative and the location only of their testing. The COVI-PASS(TM) Digital Health Passport can be used as an authenticated gateway for Public Services, Businesses and Employees to manage a safe return to work, life, and safe travel.Commenting on the deal VST Enterprises CEO Louis-James Davis said; "We are delighted to be working with CPE to supply our VCode(R) & VPlatform(R) technology and Digital Health Passport to create COVI-PASS(TM). It is also very encouraging that so many Governments and Enterprises across the world are engaging and using the COVI-PASS(TM) Health Passport and approved testing kits.We firmly believe that the digital Health Passport alongside Government approved testing kits is the key to removing the lockdown restrictions in a gradual and controlled way. The current technology being trialed using bluetooth and proximity apps is fundamentally flawed because of its privacy issues of real time tracking, the security and data breaches which we are already seeing and being reported and the reticence for citizens to uptake and download the tracing app."The Manchester based company are also in advanced discussions with senior UK Government officials, NHSX the technology arm of the NHS and the Home Office about its cyber security technology. The cyber security technology developed by VSTE can be used by various sectors including critical care workers doctors, nurses and health workers in the NHS and blue light emergency services key workers. Using a VCode(R) integrated with a health passport would help get them back on the front line in a safe and controlled manner.Circle Pass Enterprises COO and Co Founder Adam Palmer said; "We are delighted to be working with Louis-James Davis and VST Enterprises to utilise the ground breaking cyber security technology of VCode(R) & VPlatform(R) to create COVI-PASS(TM) and to help tackle this global pandemic. One of the many unique features of the VCode(R) cyber security is that the VCode(R) technology can be scanned from up to 100 metres ensuring its social distancing compliance is robust and making it the only choice for a safe and secure digital health passport.We are seeing unprecedented levels of interest from Governments, Businesses and major sporting organisations for the COVI-PASS(TM) solution. Due to the secure patented technology of the VCode(R) & VPlatform(R) - its ease of use and rapid implementation globally across all sectors - it is clear that COVI-PASS(TM) is the only viable solution for a safe return to work, life and travel protocols. Unlike Bluetooth, QR, or similar proximity apps, COVI-PASS(TM) using the VCode(R) & VPlatform(R) cyber security tech does not violate privacy issues of the user."VSTE are also providing its VCode(R) & VPlatform(R) technology to work with the UNITED NATIONS as part of their SDG Collaboratory (Sustainable Development Goals) program - to provide a wide range of technology services to 9 Billion people by 2030 and which will be announced in the coming weeks.VSTE and its partner REDSTRIKE the sports marketing agency are also in advanced discussions with major global sporting organisations and regulatory bodies in F1, motorsport, football, rugby, athletics, cycling, golf, tennis and basketball, to use its VCode(R) technology to help kick start the global sports economy.REDSTRIKE MD Mike Farnan - the former Manchester United FC International MD - and his team have been pivotal in opening up high level talks with global sporting organisations.The "COVI-PASS(TM)" Health Passport User JourneyA short infomercial explains the technology at www.covipass.com- The user downloads the app to their smartphone device and onboards their key information such as name, address, age and verifies their identity using biometric fingerprint or facial scan.- The user then takes the COVID-19 test which is administered by an authorised Health Care Professional, Nurse or Doctor. The test is geo fenced to that location and the test results are then scanned from the testing kit into the COVI-PASS(TM) Health Passport.- A traffic light system then confirms their health status as either red or green, red for positive and green for negative. The amber colour indicates a countdown timer to when another test would be due and required.- The user can then show the COVI-PASS(TM) health passport to authenticate their health status. The health passport can also be scanned well outside the safe distancing zone of 2/3m (and beyond) while the person is moving and at various angles to ensure continued social distancing guidelines.VST Enterprises CEO Louis-James Davis added; "The issue at present with other health passports is that not only is the feed of information voluntary, but the technology being used (in most cases a QR code or barcode) can't be interacted with outside of the safe distancing zone. Data and sensitive information scanned or stored in either a QR code and barcode can be hacked and are inherently insecure, leaving data and personal details to be compromised. Both barcodes and QR codes are old second generation technology. VCode(R) & VPlatform(R) represent the next "third generation" of ultra secure and versatile code technology to military grade encryption with over 2 Quintillion code permutations.The technology used in contact tracing and Bluetooth proximity apps currently being used by various Governments is fundamentally flawed. Not only can the bluetooth app and its data be compromised and hacked, but it can also lead to false flag data. There are also real fundamental issues of privacy, and being tracked in real time which most citizens will resist at all levels. This will also contribute to anxiety about the technology thus resulting in poor uptake. Without 100% uptake of the population using the technology its data is ineffective, and does not give a true picture of the virus tracing. Add into this the fact that bluetooth can also penetrate glass and walls. So someone for example, who is self isolating in a house that has tested positive for COVID-19 would give off a false flag to someone walking past their house who has tested negative, that they had been in proximity to someone who has tested positive."NOTES TO EDITORSAbout VST Enterprises LtdVST Enterprises (VSTE) is the company behind the VCode(R) and VPlatform(R). Headquartered in Manchester, the company has satellite offices around the world and is operational in 16 countries.About VCode(R) & VPlatform(R)VCode(R) represents the next generation of code scanning technology - an evolutionary step forward from traditional barcodes and QR Codes. VCode(R) has an infinite range of applications and capabilities from secure identification and ID, to geo location and geo fencing, asset tracking, authentication and permission based authorisations, fan and customer engagement through to biometrics and facial recognition.VCode(R) can be used across a wide range of applications to securely purchase music, video and film content to concert and sports event tickets. It can also be used to screen exclusive film content, sales promotion and marketing and create dynamic marketing and fan engagement campaigns. Its wider uses also include anti counterfeiting and anti piracy.A VCode(R) can be scanned from over 100 metres, with a 80:1 distance to size scan ratio, at 170-degree angles, on and from moving objects, and upon any multimedia or television screen and even when the VCode(R) is microscopic on bank notes or minerals. This allows users to access exclusive content, check the validity and authenticity of an item and make purchases while on the move. VCode(R) provides military grade encryption with over 2.2 Quintillion combination codes.Supporting the VCode(R) app is the VPlatform(R) - a secure cloud based portal that allows users to create VCode(R) and manage the content they lead to. The VPlatform(R) also provides users with real time analytics on who scanned their codes, when and where the scans took place, providing vital consumer data.The VPlatform(R) enables push notifications and rewards to be sent back to individuals who have made VCode(R) scans, offering opportunities for brands to significantly enhance their engagement levels with their client base. For more information please visit www.vstenterprises.com or www.vcode.it/developersAbout Circle Pass Enterprises (COVI-PASS(TM))Circle Pass Enterprises (CPE) is a global Digital Health Technology Company. Circle Pass Enterprises, which owns COVI-PASS(TM), has offices in London, Dublin, Amsterdam, Dubai, New York, Hong Kong and Chennai. Supported by a number of leading scientists and medical professionals, the CPE executive leadership team are developing digital Health Technology solutions for global application. For more information please visit www.covipass.com Trintech Extends Reporting Capabilities in Its Adra Suite with the Launch of Adra Analytics 2020-05-04T16:09:45Z trintech-extends-reporting-capabilities-in-its-adra-suite-with-the-launch-of-adra-analytics      May 5, 2020 - As a leading provider of financial software solutions, Trintech today announced the launch of Adra Analytics, extending the reporting capabilities of its Adra Suite. This solution ensures companies have full visibility into their financial data in one consolidated location, giving them a one-stop-shop for all their financial reporting needs."Adra Analytics has given us full visibility into the quality and efficiency of our close process," said Wojciech Bec, Financial Controller at Unit4. "We can identify which areas we are doing well, and which areas need improvement. This insight has enabled us to accelerate our financial close process significantly."With Adra Analytics, organizations can now track the trends and movements of their financial data throughout one period, or over several, to give them greater insight into how their company is maturing. It allows organizations to combine financial data within the Adra Suite with data from other solutions, such as their ERP, through a BI toolkit, to give them complete insight into their month-end alongside non-close related activities. Through customized dashboards organizations gain visibility into high-level summaries of their data and they also provide the ability to deep dive into the details required to analyze how their month-end is impacting the overall company's financials."As a leading financial software provider, we know that a company's financial data is mission critical, especially during a time like this," said Darren Heffernan, President, Mid-Market at Trintech. "Finance & Accounting (F&A) organizations are even more integral to their businesses because they have the data that are driving those immediate business decisions. To help provide that real-time visibility into the financials, we are thrilled to announce the launch of Adra Analytics that will help F&A organizations gain those insights quickly to help drive the strategic directions of their organizations."Currently deployed by over 1,800 companies across the globe, the Adra Suite provides cloud-based, financial close and reconciliation solutions for companies looking to quickly increase the efficiency, control and visibility for all key areas of the financial close process including: balance sheet reconciliations (Adra Balancer), transaction matching (Adra Matcher), financial task management and controls (Adra Task Manager), and reporting (Adra Analytics).About TrintechTrintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting and bank fee analysis, to governance, risk and compliance - Trintech's portfolio of financial solutions, including Cadency(R) Platform, Adra(R) Suite, and targeted tools, ReconNET(TM), T-Recs(R), and UPCS(R), help manage all aspects of the financial close process. Over 3,500 clients worldwide - including the majority of the Fortune 100 - rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands and the Nordics, as well as strategic partners in South Africa, Latin America and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook and Twitter. Trintech and The Hackett Group Announce Strategic Partnership to Help Organizations Transform the Close 2020-04-22T17:15:42Z trintech-and-the-hackett-group-announce-strategic-partnership-to-help-organizations-transform-the-close Apr 23, 2020 - Trintech, a leading global provider of integrated Record to Report software solutions for the office of finance, and The Hackett Group, Inc. (HCKT), an intellectual property-based strategic consultancy and leading enterprise benchmarking and best practices digital transformation firm to global companies, today jointly announced a strategic alliance to deliver finance solutions that empower organizations to deliver real-time financial intelligence to executives and add strategic value to the enterprise."The demand for Record to Report technology solutions continues to grow as finance organizations around the world seek to increase not only the efficiency, but also the effectiveness of their financial close," said David Dungan, Vice Chairman and COO of The Hackett Group. "We believe this strategic partnership with Trintech will offer customers a comprehensive solution that will drive true financial transformation."With this strategic alliance, Trintech and The Hackett Group will provide CFO and CIO organizations with effective finance processes and technology solutions that optimize efficiencies, visibility, governance and controls across the entire Record to Report process. By improving and automating these operations, Trintech and The Hackett Group will help the office of the CFO reduce costs and risk and allow them to free up valuable resources to refocus their time and effort on other initiatives critical to the business."We are confident that organizations committed to digitally enabling and transforming their financial processes will benefit immensely from the combination of Trintech's System of Accounting Intelligence(TM) and The Hackett Group's expertise in helping businesses simplify, standardize, and automate their processes," said Russ Hubbard, Chief Revenue Officer at Trintech. "Together, we aim to help finance organizations become simpler, agile and more efficient."With this partnership, Trintech's customers will be able to extend and augment the benefits they have experienced from utilizing Trintech's leading Record to Report solution by engaging The Hackett Group's empirical benchmarks, intellectual property, and focused consulting capabilities that detail how companies can improve efficiency and effectiveness and quantify world-class and peer performance. The Hackett Group's research also spotlights strategic thinking in financial transformation strategy, best practices and emerging areas - including the increasing use of digital transformation such as robotic process automation and artificial intelligence.About The Hackett GroupThe Hackett Group (HCKT) is an intellectual property-based strategic consultancy and leading enterprise benchmarking and best practices digital transformation firm to global companies, offering digital transformation including robotic process automation and enterprise cloud application implementation. Services include business transformation, enterprise analytics, working capital management and global business services. The Hackett Group also provides dedicated expertise in business strategy, operations, finance, human capital management, strategic sourcing, procurement and information technology, including its award-winning Oracle and SAP practices.The Hackett Group has completed more than 15,000 benchmarking studies with major corporations and government agencies, including 97% of the Dow Jones Industrials, 89% of the Fortune 100, 87% of the DAX 30 and 59% of the FTSE 100. These studies drive its Best Practice Intelligence Center(TM) which includes the firm's benchmarking metrics, best practices repository and best practice configuration guides and process flows, which enable The Hackett Group's clients and partners to achieve world-class performance.More information on The Hackett Group is available at: www.thehackettgroup.com, info@thehackettgroup.com, or by calling +1-770-225-3600.Hackett Cautionary Statement Regarding "Forward Looking" StatementsThis release contains "forward looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements including without limitation, words such as "expects", "anticipates", "intends", "plans", "believes", seeks", "estimates" or other similar phrases or variations of such words or similar expressions indicating, present or future anticipated or expected occurrences or outcomes are intended to identify such forward looking statements. Forward looking statements are not statements of historical fact and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that may impact such forward looking statements include without limitation, the ability of Hackett to effectively market and continuing demand for Trintech software, its digital transformation and other consulting services, competition from other consulting and technology companies who may have or develop in the future, similar offerings, the commercial viability of Hackett and its services as well as other risk detailed in Hackett's reports filed with the United States Securities and Exchange Commission. Hackett does not undertake any duty to update this release or any forward looking statements contained herein.About TrintechTrintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting and bank fee analysis, to governance, risk and compliance - Trintech's portfolio of financial solutions, including Cadency(R) Platform, Adra(R) Suite, and targeted tools, ReconNET(TM), T-Recs(R), and UPCS(R), help manage all aspects of the financial close process. Over 3,500 clients worldwide - including the majority of the Fortune 100 - rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands and the Nordics, as well as strategic partners in South Africa, Latin America and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook and Twitter. 2000 km on a Single Charge: Brighsun's Li-S Batteries to Enter Industrial Trials 2020-04-21T21:32:47Z 2000-km-on-a-single-charge-brighsun-s-li-s-batteries-to-enter-industrial-trials FRANKSTON, AUS, Apr 22, 2020 - (ACN Newswire) - Lithium batteries will soon power Electric Vehicles (EVs) traveling 2,000 km on a single charge, say the team at Brighsun New Energy. The company is preparing for industrial trials later in the year for a range of lithium-sulfur (Li-S) batteries that can power a cell phone for over a week and can theoretically travel close to 2,000 km on a single charge. The revolution is underway. Lithium Sulfur (Li-S) Battery Technology BreakthroughThrough nearly 8 years of research, the Brighsun team developed lithium-sulfur (Li-S) batteries with an energy density 5-8 times higher than conventional secondary batteries. According to results from an internationally accredited testing agency (SGS), Brighsun's new technology allows an Li-S battery to keep 91% of its initial capacity after 1,700 cycles at a rate of 2C (being fully charged/discharged in 30 mins). That means the capacity decay per cycle is as low as 0.01%. Even at a more aggressive rate of 5C (being fully charged/discharged in 12.5 mins), Brighsun's Li-S battery retains 74% of its initial capacity after 1,000 cycles (capacity decay per cycle of 0.026%). The cathode energy density for the 1th cycle after activation at charge rate of 1C is 2103.8Wh/kg.Driven by the growing markets world-wide for EVs, the battery industry has explored a range of chemical combinations: lithium iron phosphate, lithium cobalt oxide and, currently, nickel manganese cobalt. However, current battery systems still suffer from the major disadvantages of relatively low energy density, high raw material costs and secondary pollution during recycling.A Game ChangerBrighsun's advanced Li-S chemistry, offering high energy density and resultant low raw material costs, will be a game changer in the EV industry. Li-S batteries also have the potential to become the most promising energy storage systems for future railways, ships and airlines. Industries such as electric supply grid storage, mobile phones, drones and AI will also benefit from dramatically higher energy density storage provided by Brighsun's new battery system.Companies in the US, Germany, Korea and China have been developing Li-S batteries and have achieved promising breakthroughs. However, these systems still face a number of challenges, including volume expansion of cathode materials during cycling, the shuttling effect of polysulfides, and the dendritic growth of lithium on the anode. This results in shorter cycling life and poor fast-charging capability, both major obstacles to their application in the world automotive industry.Brighsun's Revolutionary ApproachBrighsun has patented Li-S battery technology that prevents the generation of polysulfide on the sulfur cathode and effectively suppresses dendritic growth of Li on the anode Li-S, paving the way for Li-S battery use in EVs.The company has already developed processes for the production of cathode materials (electrolytes, separators and lithium sheet anodes), of which the core materials (anodes, electrolytes, and separators) can be produced in batches. Trial production of high-power cells with an expected energy density in excess of 1,000 Wh/kg is about to begin. Brighsun is also developing a solid-state electrolyte compatible with its Li-S system, aiming at further improvements in the cycling life, energy density and safety of its Li-S batteries.Plentiful and Low Cost Battery MaterialsThe main raw materials for Brighsun's Li-S batteries are widely available in Australia, with a supply sufficient for hundreds of years. Indeed, at under AUD100 for 1kWh, the expected production cost of Brighsun-branded 2U Li-S batteries is lower than conventional lithium ion batteries - providing a major boost to the development of electric vehicle and related industries in Australia and around the world.Going ForwardBrighsun is currently in discussion with potential investors in the large-scale trial production of Li-S batteries. The development process for large-scale production is expected to be finished by end-2020, followed by the mass production of Li-S batteries.Brighsun's new energy-dense Li-S battery is expected to accelerate EV take-up around the world, spurred by dramatically improved single-charge travel performance, low cost and long life. Combined with the relative simplicity of EV design compared to internal combustion engine/hybrid vehicles, consumers and the industry alike are set to benefit from lower cost, emission-free transport. At the same time, Brighsun's 2U Li-S batteries offer huge benefits to the mobile phone and solar-electric storage industries, generating dramatic performance improvements in both.About Brighsun EV GroupBrighsun sees its EV technology as a contribution to society's need for more cost effective and less polluting transport. Our Head Office is in Australia and focuses on using new energy technology to produce market ready solutions. Our intellectual property is fully owned by Brighsun and patented in Australia. Our technology comes from our research & development, critical to maintaining our competitive edge. We are building a production base built on our world leading technologies in lithium batteries, and expanding our Zhejiang battery production. For information, please visit http://www.brighsun.com/Index_En.asp.BrighsunSherry XiaoFrankston, Australiakevinhuang@brighsun.comhttp://www.brighsun.com Trintech Offers Cadency Close Management at No Cost to Help Large Enterprises Manage Their Close Process Virtually 2020-04-15T16:14:09Z trintech-offers-cadency-close-management-at-no-cost-to-help-large-enterprises-manage-their-close-process-virtually Apr 16, 2020 - As finance & accounting (F&A) teams adjust to a new way of working with a dispersed remote workforce, Trintech announces that its enterprise-grade Cadency Close Management solution will be available at no cost, for up to 6 months, to help large enterprises manage their close process virtually. With this offer, Trintech's professional services team will assist in the implementation and configuration of the solution including building, organizing and importing your close checklist into Cadency. In addition, they will provide training and support to help your team achieve greater visibility and control, leading to a more resilient organization."We operate in 40 countries, have 225 entities, and buy 6-12 companies a year," said Jim Agnew, SVP Corporate Controller at Ingram Micro, Inc. "With Cadency Close, we have visibility into the financial close process daily, as well as harmonization and standardization across all our countries and entities. So, a close process being done in Peru is the same process being done in Germany or the United States."Cadency Close Management integrates with all key Record to Report activities including account reconciliation and certification, journal entry management and compliance, quickly preventing "white space" breakdowns. With a dashboard-driven management framework, the solution allows your finance team to identify bottlenecks and communicate potential issues early and often, greatly reducing the possibility of missed deadlines. In addition, an eBinder creates a thorough record of all actions, making it easy to retrace every facet of the financial close. According to a third-party research study, Cadency Close Management customers have seen up to a 30% reduction in time to complete close tasks and up to a 99% reduction in time to support external auditors."Transparency, automation and standardization have always been critical to Finance & Accounting organizations, but the transition to a completely remote workforce has only exacerbated this need," said Teresa Mackintosh, Chief Executive Officer at Trintech. "As a trusted advisor to finance and accounting professionals across the globe, we want to ensure we are providing these organizations with as many resources as possible to help drive their businesses forward and alleviate some stress during this time. This offering will provide new and existing customers increased visibility and control, leading to a more resilient organization."Included with the offering of the Cadency Close Management solution, organizations can gain full access to Trintech's Customer Success Center consisting of educational online resources and self-led training materials, a knowledge base, and forums where you can ask questions and share best practices with other Cadency Close Management users."During this unprecedented time, Cadency along with our teams have helped to ensure the accuracy and quality of our financial statements while working remotely," said Jackie Peters, General Accounting Design, Process and Systems Senior Manager at HP.Trintech is also working very closely with our strategic partners, such as KPMG LLP, to help customers adapt to this new environment and prepare them for what to expect. Trintech and KPMG will be hosting a virtual panel on Thursday, April 16th, to give companies insight into topics like, how this new way of working will affect the next audit cycle, how to conduct a virtual close, and the risks to consider from a cybersecurity perspective when working in a virtual environment."With the global workforce shifting to new delivery models, we've seen clients that have embraced technologies such as Cadency more quickly in order to adapt to unique circumstances brought about by COVID-19," said Scott Cohen, Advisory, KPMG LLP. "It is more important than ever to strengthen organizations through technology and promote collaboration, remote etiquette, and visibility as we navigate our recovery and new reality."If you are interested in using the Cadency Close Management solution, you can contact us here to get started. https://go.trintech.com/Cadency-Close-Offer-NA.htmlSome or all of the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.About TrintechTrintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting and bank fee analysis, to governance, risk and compliance - Trintech's portfolio of financial solutions, including Cadency(R) Platform, Adra(R) Suite, and targeted tools, ReconNET(TM), T-Recs(R), and UPCS(R), help manage all aspects of the financial close process. Over 3,500 clients worldwide - including the majority of the Fortune 100 - rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands and the Nordics, as well as strategic partners in South Africa, Latin America and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook and Twitter.About KPMG LLPKPMG is one of the world's leading professional services firms, providing innovative business solutions and audit, tax, and advisory services to many of the world's largest and most prestigious organizations. KPMG is widely recognized for being a great place to work and build a career. Our people share a sense of purpose in the work we do, and a strong commitment to community service, inclusion and diversity, and eradicating childhood illiteracy. Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities. KPMG LLP is the independent U.S. member firm of KPMG International Cooperative ("KPMG International"). KPMG International's independent member firms have 219,000 professionals working in 147 countries and territories. Learn more at www.kpmg.com/us. Trintech Partners with Sage to Help Businesses Simplify and Accelerate Financial Close Processes 2020-04-02T17:10:25Z trintech-partners-with-sage-to-help-businesses-simplify-and-accelerate-financial-close-processes Apr 3, 2020 - Trintech, a leading global provider of integrated Record to Report software solutions for the office of finance, today announced a technology partnership with Sage to help companies simplify and accelerate financial close processes. As part of this partnership, Trintech has created a pre-built, Sage Intacct-certified connector for its Adra Suite, allowing companies to reduce the cost and time associated with data integration between the two solutions."With this Trintech partnership, businesses leveraging the powerful cloud financial management capabilities of Sage Intacct can seamlessly integrate with Trintech's Adra Suite to achieve greater visibility and control over their financial close process," said Eileen Wiens, VP of Business Development for Sage Intacct.Currently available in the Sage Intacct Marketplace, Trintech's pre-built, Sage Intacct-certified connector automatically retrieves the data required in the reconciliation and close process, removing manual processing requirements and reducing dependency on internal IT organizations. The connector leverages Sage Intacct APIs to obtain open accounts, limits the request to specific accounts, and retrieves GL balance or transactions for integration with the Adra Suite. With this integration, organizations remove ongoing support and custom code costs - increasing the organizations ROI."The combination of Sage Intacct and our Adra Suite helps companies establish an operational framework to reduce expense and time, while better fulfilling organization expectations," said Darren Heffernan, President, Mid-Market at Trintech. "Together, we provide innovative solutions that help finance and accounting teams achieve shorter close cycles and better controls, enabling them to focus their time and effort on helping achieve the strategic directions of their organizations."Deployed by over 1,800 companies across the globe, the Adra Suite provides cloud-based, financial close and reconciliation solutions for companies looking to quickly increase the efficiency, control and visibility for all key areas of the financial close process including: balance sheet reconciliations (Adra Balancer), transaction matching (Adra Matcher), and financial task management and controls (Adra Task Manager).Businesses interested in the Adra Suite or Sage Intacct solution can request more information at https://www.trintech.com/adra/schedule-a-demo/ or on the Sage Intacct Marketplace.About TrintechTrintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting and bank fee analysis, to governance, risk and compliance - Trintech's portfolio of financial solutions, including Cadency(R) Platform, Adra(R) Suite, and targeted tools, ReconNET(TM), T-Recs(R), and UPCS(R), help manage all aspects of the financial close process. Over 3,500 clients worldwide - including the majority of the Fortune 100 - rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands and the Nordics, as well as strategic partners in South Africa, Latin America and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook and Twitter. Trintech Offers Adra Task Manager at No Cost to Help Organizations Close Their Books Confidently While Working Remotely 2020-03-30T17:44:15Z trintech-offers-adra-task-manager-at-no-cost-to-help-organizations-close-their-books-confidently-while-working-remotely Mar 31, 2020 - In the midst of the current crisis, many finance & accounting (F&A) teams across the globe are navigating unchartered waters as they approach month end close with a dispersed remote workforce. As a leading provider of financial software solutions, Trintech announced today that its best-in-class Adra Task Manager solution will be available at no cost, for up to 6 months, to help mid-sized organizations close their books confidently while they work remotely. This SaaS-based solution is deployed remotely and can be up and running in minutes, fully functional within a day or two, ensuring accuracy and simplifying your existing processes.Diane Foss, Director of Finance at Genesis Systems recently stated, "I'm really glad we implemented both Adra Task Manager and Balancer, especially with the current situation. We do have quite a few of our departments working from home now and Adra will help so much in keeping track of where we are at with our upcoming close since we aren't a shout away from each other."With Adra Task Manager, task lists are built with clear and concise instructions that create ownership and accountability across your remote organization. Real-time dashboards allow managers to check progress anytime and from anywhere to help identify issues that need immediate attention, and to ensure clear, efficient communication. Notifications and alerts keep teams on task, with archived comments to streamline future communications. The approval workflow and built-in segregation of duties provides needed governance and control, with an audit trail automatically created to allow for consistent tracking."As someone who has worked in Finance for 20+ years and was the previous CFO of Trintech, I know firsthand how stressful the month-end process can be, especially during a dynamic time like this," said Darren Heffernan, President, Mid-Market at Trintech. "As organizations navigate their new "normal" of working remotely, we will be offering our Adra Task Manager solution at no cost for up to 6 months to help ease this transition. This offering will provide new and existing customers increased visibility and control, helping them close their books confidently each month."In addition to the offering of the Adra Task Manager solution, organizations can gain full access to Trintech's Customer Success Center consisting of educational online resources and self-led training materials including pre-built templates that simplify setup, a knowledge base, and forums where you can ask questions and share best practices with other Task Manager users.If you are interested in using the Adra Task Manager solution, you can contact us here to get started. https://go.trintech.com/AdraTaskManager-Offer.htmlCurrently deployed by over 1,800 companies across the globe, the Adra Suite provides cloud-based, financial close and reconciliation solutions for companies looking to quickly increase the efficiency, control and visibility for all key areas of the financial close process including: balance sheet reconciliations (Adra Balancer), transaction matching (Adra Matcher), and financial task management and controls (Adra Task Manager).About TrintechTrintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting and bank fee analysis, to governance, risk and compliance - Trintech's portfolio of financial solutions, including Cadency(R) Platform, Adra(R) Suite, and targeted tools, ReconNET(TM), T-Recs(R), and UPCS(R), help manage all aspects of the financial close process. Over 3,500 clients worldwide - including the majority of the Fortune 100 - rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, France, Germany, Ireland, the Netherlands and the Nordics, as well as strategic partners in South Africa, Latin America and the Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook and Twitter. Coronavirus Drug Development Update from NanoViricides, Inc. 2020-03-18T14:53:01Z coronavirus-drug-development-update-from-nanoviricides-inc      Mar 16, 2020 - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19.The Company has completed the synthesis of a number of nanoviricide drug candidates for testing in just a few weeks after identification of virus-binding ligands. This was possible because the Company is boot-strapping its efforts on the basis of its inventory of novel custom chemicals in hand. Additionally, the polymer backbone was previously manufactured in multi-kilogram quantities. However, there can be no assurance that any of these candidates would show sufficient effectiveness and safety for human clinical development at this time.The Company has acquired and expanded two different, low-threat circulating coronaviruses in its own BSL2 lab, and has already expanded them to enable testing of drug candidates. One of these coronaviruses, namely NL63, uses the same ACE2 receptor on human cells as SARS-CoV-2, although it does not cause a similar severe disease in humans.If the Company's test candidates are effective against these cell culture studies against coronaviruses, then that would provide a strong rationale that they may be expected to be effective against the current SARS-CoV-2. Presently, the Company does not have any collaboration established for further testing of its drug candidates against SARS-CoV-2. The Company is working to establish such collaborations, however, there can be no assurance that we will be successful in establishing the necessary collaborations or that our drug candidates will succeed in further testing. In the past, the Company has established and worked on collaborations with the U.S. Center for Diseases Control and Prevention (CDC), as well as the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).The Company has already successfully developed antiviral drug testing assays based on cell culture infection of certain low-threat coronaviruses viruses in our own BSL2 certified virology lab. Development of an assay to test the effectiveness of a drug candidate is an important milestone in the drug development process. We have been able to complete this milestone in just a few weeks because of the extensive experience and expertise in medium throughput drug testing antiviral assays development of our Senior Virologist.Testing of our drug candidates against these BSL2 coronavirus strains is expected to begin shortly in our BSL2 virology lab.As of March 11th, SARS-CoV-2 has caused at least 800 confirmed cases in more than 30 states, and the virus has led to more than 26 deaths in the U.S., with area lockdowns, quarantines, and state of emergency being declared in several states. The entire country of Italy is under quarantine. Japan is also experiencing a severe outbreak. This COVID-19 outbreak has caused cases in at least 99 countries, with confirmed cases totaling over 110,000, of which 62,000 have already recovered, with deaths of over 3,800 patients, according to CBS news (https://www.cbsnews.com/live-updates/coronavirus-outbreak-death-toll-us-infections-latest-news-updates-2020-03-09/). The health risks associated with the virus rise significantly with age and many younger, otherwise healthy people who contract it might show only mild symptoms, if any. It appears that the outbreaks in China and in South Korea are now showing signs of being controlled, with new cases having decreased significantly.The U.S. Government has approved $8.3 Billion for COVID-19 response that includes development of drugs as well as vaccines, patient care, containment, and education, in a holistic approach.Although vaccine development has started very quickly against the SARS-CoV-2, an effective vaccine may take at least 12-18 months before it can be used to treat patients.Viruses are known to escape antibody drugs and vaccines via mutations, although, in contrast, the NanoViricides platform technology enables development of a drug that a virus is unlikely to escape by mutation. This is because we develop biomimetics that are designed to interfere with the virus binding to its cognate cellular receptor, and are further capable of disabling the virus from binding to cells. Coronaviruses mutate less rapidly than other RNA viruses such as influenza and HIV.One of the coronaviruses we are using for testing of our drug candidates uses the same ACE2 receptor as the current SARS-CoV-2 virus (aka nCoV-2019). However, this coronavirus does not cause similar, severe disease in humans. Another coronavirus we are testing against uses a different but somewhat related receptor (in terms of biophysics). Investigating against both of these strains would allow us to examine which of the test candidates have more broad-spectrum effectiveness. However, there can be no assurance that successful results against these forms of coronavirus will lead to similar results against nCoV-2019 aka SARS-CoV-2. Moreover, the path to typical or standard drug development of any pharmaceutical product is extremely lenghty and requires substantial capital. However, regulatory agencies in China created expedited processes to enable rapid clinical testing of exploratory drug candidates. Accelerated pathways were also developed for enabling anti-Ebola clinical drug candidates in the 2017-18 epidemic in DRC. Nevertheless, there can be no assurance that even successful results against SARS-CoV-2 will lead to successful clinical trials or a successful pharmaceutical product, which is true of every drug development effort against SARS-CoV-2 at present.Previously, on January 30th, the Company confirmed that it is working on a drug to treat the SARS-Cov-2 virus infections. The Company said that it had successfully completed the important milestone of finding potential virus-binding ligands that mimic the ACE2 interaction with SARS-CoV (2002) using molecular modeling. The current coronavirus strain, namely SARS-CoV-2 is closely related to the 2002 SARS-CoV, and uses the same human cellular receptor. We have now completed the next two milestones, namely synthesis of test candidates, and development of anti-CoV assays for testing them.About NanoViricidesNanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company does not currently have a license to the coronavirus field, however, TheraCour has not denied any licenses to the Company. The Company typically begins the licensing process only after demonstrating effectiveness of some candidates in optimization stage.This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. CMC refers to "Chemistry, Manufacture, and Controls".Contact:NanoViricides, Inc.info@nanoviricides.comPublic Relations Contact:MJ ClyburnTraDigital IRclyburn@tradigitalir.comSOURCE: NanoViricides, Inc. Aruba's Global Cloud Data Center enhances international accessibility with new Cogent PoP 2020-03-15T22:30:30Z aruba-s-global-cloud-data-center-enhances-international-accessibility-with-new-cogent-pop Mar 16, 2020 - Aruba S.p.A., a leader in data centre and cloud enterprise services, has announced the activation of a new presence point within its Global Cloud Data Center, based at its technology campus on the outskirts of Milan, provided by leading global internet service provider Cogent.The point of presence will allow Aruba customers to benefit from Cogent's extensive international network that extends across North America, Europe and Asia through more than 92,000km of intercity fibre and over 56,000km of metro fibre. This network provides services to over 204 markets and connects 6,840 additional networks.The presence of an operator of this calibre - in addition to the others already partnered with Aruba - increases the range of carriers available within the Global Cloud Data Center. This gives customers access to a broader range of choices. The Global Cloud Data Center, like all Aruba data centres, is carrier-neutral and hosts numerous telecommunications operators with which customers can independently manage their relationships. Cogent now represents a new tier 1 option, joining TIM, Fastweb, Wind-Tre, Retelit, Irideos, Planetel and Vodafone.The offer of multiple connections, together with the perfect mix of Italian and international operators, allows Aruba to guarantee the highest standards in terms of performance and redundancy.Lorenzo Giuntini, CTO of Aruba commented: "This partnership adds great value to our offering. An operator like Cogent, a tier one service provider of international calibre, gives the Global Cloud Data Center appeal on a global scale and offers numerous benefits to customers thanks to the quality of the internet transit."Peter Menig, Sales Director of Cogent commented: "As the world becomes increasingly interconnected, carrier-neutral connectivity options like the one provided by the Global Cloud Data Center become more important. Cogent is pleased to have the opportunity to deliver high-quality IP transit services to Aruba data centre customers."Last year, Aruba announced the activation of a Point of Presence in the Milan Internet eXchange (MIX) - among the first in Europe and the largest Italian Internet eXchange in terms of vehicular traffic - directly accessible from the Global Cloud Data Center. The agreement provided the addition of new interconnections thanks to the use of a double fibre route to connect the equipment to Milan, thereby facilitating traffic exchange with numerous other national and international carriers.This new activation marks the next step in the expansion of the Aruba Data Center network, which already has two new Data Centers arriving within the Global Cloud Data Center technological campus area. This growth will enable Aruba to provide the highest quality of service to all its customers, whether they are national or international.For more information http://aru.ba/dcconnectivityAruba S.p.A.Aruba S.p.A., founded in 1994, is the leading company in Italy for data centers, web hosting, email, certified email (PEC) and domain registration services. Aruba is also active in key European markets including France, the UK and Germany, and is the leader in the Czech Republic and Slovakia, with an established presence in Poland and Hungary. The company has a huge amount of experience in the management of data centers, with a European network capable of hosting over 200,000 servers.Aruba manages 2.7 million domains, 8.6 million email accounts, 6.7 million certified email (PEC) accounts, 130,000 physical and virtual servers and a total of around 5.4 million customers. The company provides hosting services, public and private cloud services, housing and colocation services, dedicated servers, digital signature services, digital preservation, e-billing, certified email, SSL certificates and smart-cards.Thanks to Aruba Business, founded in 2015, it offers all the services to a vast network of IT partners, and with Pratiche.it brand, the company provides document delivery and recovery services throughout Italy. In the same year, the Aruba.it Racing, Official Ducati Team in the World Superbike World Championship was born.Since 2016 it has been the Official Registry for the prestigious ".cloud" extension. For over 10 years, Aruba Enterprise has been offering Cloud, Data Center and Trust Service solutions to businesses and public authorities, designing, implementing and managing highly customized IT solutions. For further information: https://www.aruba.it. Holista Partners GICC LLC, the U.S. Developer of Path-Away(R), to Co-Develop Nasal Sanitising Balm for Global Markets 2020-02-24T06:08:16Z holista-partners-gicc-llc-the-u-s-developer-of-path-away-r-to-co-develop-nasal-sanitising-balm-for-global-markets Feb 20, 2020 - KUALA LUMPUR/PERTH/BLUFFTON  - Holista CollTech (ASX:HCT) ("Holista") announced today it will co-develop and produce in Malaysia the world's first nasal sanitising balm using Path-Away(R), a plant-based alcohol-free active ingredient that has proven successful in killing all previously tested corona type viruses without harming humans.Path-Away(R), which has been tested and proven to kill more than 170 pathogens (including viruses, bacteria, and fungi), was developed by Global Infection Control Consultants LLC ("GICC LCC"). It kills the AIDS virus and the resilient Mycobacterium tuberculosis. In Malaysia, it is approved by the Ministry of Health as being effective against the H1N1 virus. GICC LLC, based in Bluffton, South Carolina, was founded by President and Principal Research Scientist, Dr Arthur Martin.CO-DEVELOPMENT OF NASAL SANITSING BALM FOR GLOBAL MARKETSDr Martin and Dr Rajen Manicka, founder and CEO of Holista, jointly announced, "following the outbreak of Covid-19, the two companies will extend their partnership and accelerate the development of the nasal sanitising balm which will contain Path-Away(R)".The two companies expect to jointly file a global patent on the nasal sanitising balm first quarter of 2020, and intend to commence production by the third quarter of 2020, ahead of distribution to global markets and the onset of the UK and European winter.The balm will include Path-Away(R), which is created from a series of individual plants and processes proprietary to GICC LLC. Path-Away(R) attaches to the virus and weakens the cell walls by inhibiting its ability to take up amino acids - the basic building block of cells. This forces the virus cells to clump together, in the process of killing themselves, almost instantly.Dr Martin said "An airborne virus can only enter the human body through the eyes, the mouth and the nose. The mouth is protected by salivary enzymes and the eyes produce tears with specific enzymes that disable proteins on virus surfaces. The nose, however, is warm, damp and dark especially during winter. Rich in fatty and amino acids, the nasal passage leads directly to sinuses, the throat and of course, the lungs, thus making it the most vulnerable to viruses.""We are pleased to partner with Holista to develop a nasal sanitising balm equivalent of NatShield(TM) Sanitizer as masks do not provide complete protection to the nose as they are loose-fitting and may allow small droplets to enter the mouth or nose. Since Path-Away(R) is plant-based and alcohol-free, it does not irritate the nose and will be effective for six hours", he added.UPDATE ON HAND-HELD SANITISER; APPOINTMENT OF BOTTLERS IN THE PHILIPPINESThe hand-held NatShield(TM) Sanitiser, containing Path-Away(R) and developed by Holista is currently bottled in Malaysia and distributed within the 10-country ASEAN region. Stocks have run out in local pharmacies and Holista said today it has appointed three bottlers in the Philippines to meet orders.Dr Rajen Manicka, CEO of Holista CollTech, said, "Due to health concerns about Covid-19, Holista is striving to meet the demands for the hand-held NatShield(TM) Sanitiser locally in Malaysia as well as in Australia".DISTRIBUTION EXTENDED BEYOND ASEAN TO INCLUDE THE UK AND EUROPEGICC LLC has agreed to grant Holista marketing and distribution rights of Path-Away (R) beyond ASEAN region to include UK and Europe. Holista will distribute NatShield(TM) Sanitiser and the nasal sanitising balm into the UK and Europe. Holista will also work collaboratively with GICC LLC in the North American market to market NatShield(TM) Sanitiser and the nasal sanitiser balm."We are also grateful to Dr Martin and GICC LCC for granting Holista the distribution rights for Path-Away(R) to include the UK and Europe. We are excited to collaborate Dr Martin's team in the North American market on the Natshield(TM) Sanitiser," he added.EQUIPMENT TO CLEANSE AIRFLOW IN BUILDINGS & FACILITIESUnder the leadership of Dr Martin, a trained engineer, GICC LCC has also developed a set of equipment and processes that helps deploy Path-Away(R) in buildings such as airports, transportation hubs, hospitals, schools and factories to improve the quality airflow. The solution involves pumping mists containing Path-Away(R) into the air condition and ventilation systems to destroy the deadly pathogens present in such enclosed public spaces.It has been used for over a decade in various countries and market segments to prevent illness and to increase productivity.GICC LLC has previously helped Malaysia during the H1N1 outbreak in 2009 and Singapore during the SARS outbreak in 2003 using Path-Away(R).Holista will now exclusively represent this technology in the Asia Pacific region except for China, Macau, Hong Kong and Taiwan.FUNDING UPDATEAs announced to the ASX earlier this month, the Company has successfully raised just over $2,600,000 since the start of 2020, utilising the Acuity Capital Control Placement Agreement (CPA) facility. This funding will provide the capital to develop the nasal sanitising balm, grow existing regional markets as well as new European markets without disrupting business operations.About Holista CollTech LtdHolista CollTech Ltd ("Holista") is a research-driven biotech company, the result of a merger between Holista Biotech Sdn Bhd and CollTech Australia Ltd. Headquartered in Perth and with extensive operations in Malaysia, the company is dedicated to delivering first-class natural ingredients and wellness products globally. Holista is a leader in the research of herbs and ingredients for the making of healthier food.Listed on the Australian Securities Exchange (ASX:HCT), Holista researches, develops, manufactures and markets "health-style" products to address the unmet and evolving needs of natural medicine. Holista's suite of ingredients, among other things, includes low-GI baked products, reduced-sodium salts, low-fat fried foods and low calories sugar without compromising taste, odour and mouthfeel. Holista remains the only company to produce sheep (ovine) collagen using patented extraction methods. For more information, please refer to http://www.holistaco.comContact:Corporate Affairs & Business OpportunitiesDr Rajen Manicka: rajen.m@holistaco.comGeneral Enquiries: enquiries@holistaco.comMedia and Investor Relations:WeR1 Consultants Pte LtdE: holista@wer1.net; P: +65 67374844 Yowie Group Donates to WIRES Wildlife Rescue to Aid in Australian Bushfire Relief 2020-02-18T23:35:26Z yowie-group-donates-to-wires-wildlife-rescue-to-aid-in-australian-bushfire-relief Feb 19, 2020 - Yowie Group, the confectionary company bringing families sweet treats combined with an educational experience, today announced the donation of $20,000 to WIRES Wildlife Rescue as a result of their charity donation competition. Over the holiday season, Yowie gave their fans the opportunity to vote for an eco-conservation organization of their choice. The majority of fans directed their votes to WIRES, an Australian wildlife rescue organization, in the wake of the bushfire crisis.WIRES Wildlife Rescue is the largest wildlife rescue and rehabilitation charity in Australia. It is a non-profit organization providing rescue and rehabilitation for all native Australian fauna. All animal rescuers and caretakers are volunteers. Recently, Australia has faced its worst national emergency to date, with bushfires impacting and destroying ecosystems and species across multiple states."With headlines reaching the United States about the tragic bushfires in Australia, Yowie fans were quick to want to help the animals from down under," said Cynthia Thayer, Global CMO of Yowie Group. "We are happy to be donating to WIRES on behalf of our consumers."With the fires destroying unprecedented amounts of habitat, food shortages have increased and lack of suitable habitat will be a significant long-term challenge for surviving wildlife. The money donated to WIRES by Yowie Group will be directed toward the relief and recovery of the animals and ecosystems affected by the bushfires.For more information about Yowie Group or WIRES, please visit yowieworld.com or wires.org.au.About YowieYowie is best known for its flagship product, the Yowie surprise inside chocolate. Each Yowie product is created in the shape of the Yowie characters (Yowie is what they call Bigfoot in Australia) and contains limited-edition collectible animal toys and a full color leaflet featuring a picture of the real-life animal, its profile and level of endangerment. Our social media channels and website allow collectors to learn more about the animals and their world while having loads of fun through games and competitions. The combination of tasty, clean-label treats, fun animal toys and an educational experience encourages kids to learn about wildlife and the threats endangered animals face. Yowie surprise inside chocolates, Yowie Bites and Yowie Gummies are available in more than 30,000 retail outlets across the U.S. For more information visit www.yowieworld.com. Trintech Announces Four SAP-Certified Integrations with SAP S/4HANA(R) and SAP NetWeaver(R) 2020-02-18T17:30:31Z trintech-announces-four-sap-certified-integrations-with-sap-s-4hana-r-and-sap-netweaver-r Feb 19, 2020 - (ACN Newswire) - Trintech, a leading global provider of integrated Record to Report software solutions for the office of finance, today announced successful certifications by the SAP Integration and Certification Center (SAP ICC). Trintech's Cadency(R) 8.0 and Cadency RPA and Journal Management (ERP Bots) have been SAP-certified for integration with both SAP S/4HANA(R) and powered by SAP NetWeaver(R). The latest certifications for Trintech also support deployment and compatibility with all earlier versions of SAP(R) software. The latest certifications include:- Trintech Cadency V8.0 for SAP ERP (Connectors to extract data out of SAP ERP and import into Cadency)- Trintech Cadency V8.0 for SAP S/4HANA (Connectors to extract data out of SAP S/4HANA and import into Cadency)- Trintech RPA and Journal Management V8.0 for SAP ERP (ERP Bots for automating Close and JE tasks within SAP ERP with bi-directional connectivity with Cadency)- Trintech RPA and Journal Management V8.0 for SAP S/4HANA (ERP Bots for automating Close and JE tasks within SAP S/4HANA with bi-directional connectivity with Cadency)"Trintech continues to reinforce its partnership with SAP by delivering new integration capabilities to provide customers with even more value in their financial transformation journeys," said Michael Ross, Chief Product Officer at Trintech. "These integrations bring enhanced control, automation and data integrity to finance and accounting departments around the world, while also helping to ensure that data flowing to and from their SAP solutions is as seamless as possible."Bi-directional in nature, Cadency reduces the cost, time and risk of data integration with SAP, by automatically retrieving the data required for the reconciliation and close processes, as well as directly validating and posting journal entries in real-time. Solutions that are SAP-certified can be more quickly and easily integrated into SAP solution environments and can reduce overall IT investment costs and risks.Trintech currently has hundreds of customers running SAP solutions alongside its enterprise solution, Cadency such as, Siemens, HP, GSK, and Ingram Micro. Although many of Trintech's customers have deployed SAP, Cadency is ERP agnostic, offering the ability to support all instances of ERPs and GL systems, including SAP, Oracle(R), NetSuite(R) and many more for complete visibility across all business units, geographies and sources.About CadencyCadency is the only System of Financial Controls that combines all financial close activities into a single, streamlined process, including operational matching, intercompany transaction management, balance sheet reconciliations, journal entry management, close task management, compliance and reporting. Through the combination of a System of Financial Controls, strong integration, and advanced automation, organizations will achieve a System of Accounting Intelligence that will ultimately allow them to shift their focus away from repetitive tasks to higher value work that helps drive the strategic directions of their organizations.About TrintechTrintech Inc., a pioneer of Financial Corporate Performance Management (FCPM) software, combines unmatched technical and financial expertise to create innovative, cloud-based software solutions that deliver world-class financial operations and insights. From high volume transaction matching and streamlining daily operational reconciliations, to automating and managing balance sheet reconciliations, intercompany accounting, journal entries, disclosure reporting and bank fee analysis, to governance, risk and compliance - Trintech's portfolio of financial solutions, including Cadency(R) Platform, Adra(R) Suite, and targeted tools, ReconNET(TM), T-Recs(R), and UPCS(R), help manage all aspects of the financial close process. Over 3,500 clients worldwide - including the majority of the Fortune 100 - rely on the company's cloud-based software to continuously improve the efficiency, reliability, and strategic insights of their financial operations.Headquartered in Dallas, Texas, Trintech has offices located across the United States, United Kingdom, Australia, Singapore, Germany, France, Ireland, the Netherlands and the Nordics, as well as strategic partners in South Africa, Latin America and Asia Pacific. To learn more about Trintech, visit www.trintech.com or connect with us on LinkedIn, Facebook and Twitter.SAP, SAP S/4HANA, SAP Netweaver and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries. Please see https://www.sap.com/copyright for additional trademark information and notices. All other product and service names mentioned herein are the trademarks of their respective owners. Shape Capital Advises SQID Technologies Ltd Listing on CSE 2020-02-12T05:21:52Z shape-capital-advises-sqid-technologies-ltd-listing-on-cse Feb 12, 2020 - Corporate advisory and investment firm Shape Capital announced today that its Brisbane based client SQID Technologies Limited successfully completed listing on the Canadian Securities Exchange "CSE" on January 21, 2020 under the symbol CSE:SQID. SQID is a payment processor enabling merchants to receive debit or credit card payments. For the fiscal year ended June 2019, SQID reported total transaction value of $163 million and revenues of $5,403,525 and profit before income tax of $1,147,722 reflecting a 72% increase in revenues and 85% increase in its profit before income tax over the same period for the fiscal year 2018.A team of advisors handled the listing with Shape Capital acting as the Australian corporate advisor to the transaction in collaboration with TriPoint Global Equities/BANQ(R) in NY and Australian based First Growth Funds Limited."Listing Australian companies on the CSE is cost effective and a more streamlined process compared to listing on the ASX. The CSE provides Australian companies with a great launch pad into North America to gain market exposure, access to new investors and help create shareholder value, said Anoosh Manzoori, CEO of Shape Capital."SQID's technology provides merchant services and transaction processing to business merchants and ecommerce customers across both 'Business to Business' (B2B) and 'Business to Consumer' (B2C) segments to bridge both retail and wholesale transactions through its platform. Its technology is powerfully structured to allow layered access to payment and merchant transaction data, and integrates these retail and wholesale layers (creating many separate customer nodes within the network), providing split settlements between each layer. This provides a broad platform for commission structures and transaction-based rewards that are settled at the same time as the underlying transaction is settled. The business model is applicable to significant business channels including affiliate marketing, rewards programs, franchises, marketplace apps, agencies, etc.SQID has established itself as a relationship payment provider and payment facilitator in the Payment Processing industry, which specialises in delivering ecommerce solutions to businesses that have their 'card-not-present' commercial outcomes dependent on two or more businesses. This has delivered sizeable growth in revenue as the model is based on engaging one referrer who then refers additional merchants. The Company has concentrated on building relationships with merchants and providing incentives to merchants for referrals to new business opportunities. This has resulted in substantial growth with minimal overhead and resources.The SQID business has a proven business model of delivering sustained profitability over time. Revenue growth has been achieved through strong growth from merchants in industries related to training and education.For further information please visit the company's corporate website at www.sqidpay.com.About Shape CapitalShape Capital is an investment and corporate advisory firm that positions, prepares and shapes clients for specific events, including mergers and acquisitions, capital raisings and IPOs. As an independent advisory firm, Shape Capital advises private and public companies and has extensive experience in cross-boarder transactions with a strong focus on the technology sector. Shape Capital works with high growth companies to assist with strategy, timing, structure, valuation, and provides access to a large global network of investors. Shape Capital holds an Authorised Corporate Representative of an Australian Financial Services License (AFSL) with head office in Melbourne, Australia. For more information, please visit http://www.shape.capital